PD-1/PD-L1 checkpoint inhibitors block the attenuation of T-cell immune function involving PD-1 on CD8+ T-cells or one of its principal counter ligands, PD-L1, on tumor cells and host immune cells. The gene discussed is CD8A; the disease is neoplasm.